AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
where ∆(APB) is the area of triangle APB. Denote the segments that the diagonal intersection P divides diagonal AC into as AP = p1 and PC = p2, and similarly P divides diagonal BD into segments BP = q1 and PD = q2. Then the quadrilateral is tangential if and only if any one of the following equalities are true:
=== Reagents === Phenol: The phenol used for biochemistry comes as a water-saturated solution with Tris buffer, as a Tris-buffered 50% phenol, 50% chloroform solution, or as a Tris-buffered 50% phenol, 48% chloroform, 2% isoamyl alcohol solution (sometimes called "25:24:1"). Phenol is naturally somewhat water-soluble, and gives a fuzzy interface, which is sharpened by the presence of chloroform, and the isoamyl alcohol reduces foaming. Most solutions also have an antioxidant, as oxidized phenol damages the nucleic acids. For RNA purification, the pH is kept at around 4, which retains RNA in the aqueous phase preferentially. For DNA purification, the pH is usually near 7, at which point all nucleic acids are found in the aqueous phase. Chloroform: Chloroform is stabilized with small quantities of amylene or ethanol, because exposure of pure chloroform to oxygen and ultraviolet light produces phosgene gas. Some chloroform solutions come as pre-made a 96% chloroform, 4% isoamyl alcohol mixture that can be mixed with an equal volume of phenol to obtain the 25:24:1 solution. Isoamyl alcohol: Isoamyl alcohol may reduce foaming and ensure deactivation of RNases.
where i is each one of the gases that adsorb. Note: 1) To choose between the Langmuir and Freundlich equations, the enthalpies of adsorption must be investigated. While the Langmuir model assumes that the energy of adsorption remains constant with surface occupancy, the Freundlich equation is derived with the assumption that the heat of adsorption continually decrease as the binding sites are occupied. The choice of the model based on best fitting of the data is a common misconception. 2) The use of the linearized form of the Langmuir model is no longer common practice. Advances in computational power allowed for nonlinear regression to be performed quickly and with higher confidence since no data transformation is required.
At the time, the California legislature was considering several AI laws that would require insurance companies to report the use of AI when denying healthcare claims, as well as regulations that would require AI to be performance tested before making implementation on certain applications. In May 2025, House Republicans inserted into a tax and spending bill a clause banning state AI laws for 10 years, which was met with opposition from more than 100 nonprofit organizations, elected officials, public policy experts, and others. The Senate voted 99-1 to defeat the ban. In September 2025, Sen. Ted Cruz (a supporter of the AI state moratorium) said that the proposal would return for debate in Congress. In June 2025, the U.S. Department of Commerce established the Center for AI Standards and Innovation (CAISI) as part of the NIST. CAISI serves as the federal government's primary point of contact for AI developers, streamlining coordination between private industry and the U.S. government on AI issues including security, evaluation, assessment, and the development of guidelines, standards, and best practices. CAISI is responsible for establishing agreements with AI industry leaders and developers to allow for federal government review processes of frontier AI models. By June 2026, Anthropic, Google, Microsoft, and OpenAI had established AI model review agreements with CAISI. In August 2025, Silicon Valley companies and investors pledged up to $200 million to two new pro-AI super PACs, Meta California (funded by Meta) and Leading the Future.
== History == In 1994 Tsutomu Nomizu and colleagues at Nagoya University performed the first mass spectrometry experiments of single cells. Nomizu realized that single cells could be nebulized, dried, and ignited in plasma to generate clouds of ions which could be detected by emission spectrometry. In this type of experiment elements such as calcium within the cell could be quantified. Inspired by Flow cytometry, in 2007 Scott D. Tanner built upon this ICP-MS with the first multiplexed assay using lanthanide metals to label DNA and cell surface markers. In 2008 Tanner described the tandem attachment of a flow cytometer to an ICP-MS instrument as well as new antibody tags that would allow massively multiplexed analysis of cell markers. By further optimizing the detection speed and sensitivity of this flow coupled to ICP-MS they built the first CyTOF instrument. The CyTOF instrument was originally owned by the Canadian company DVS Sciences but is now the exclusive product of Fluidigm after their acquisition in 2014 of DVS sciences. In 2022 Fluidigm received a capital infusion and changed its name to Standard BioTools. There have been 4 iterations of the CyTOF apparatus named CyTOF, CyTOF2, Helios™ and CyTOF XT. The successive improvements were largely in increased detection range and software parameters with the Helios instrument able to detect from metals ranging from yttrium-89 to bismuth-209 and throughput and analyze 2000 events per minute.
Sources: en.wikipedia.org
English said that a new Cold War had already begun, and that China poses a far greater threat to the West than Russia in cyberwarfare but not as much as far-right populism does from within liberal states.
One Sunday Adam comes in to work, and Cory is smoking pot with friends and listening to loud music. One day Sarah is turned down for a raise by Cory, who suggests Sarah find work that she wants to do, so Sarah quits her internship. Another weekend Cory offers Adam an "edible" lollipop and explains his idea for the shoe company; Adam thinks he understands, but is unaware that he ingested cannabis until afterwards when Crosby notices it. One day Cory fires Eddie, the design manager (who is replaced by "Spyder", Cory's friend) without Adam's knowledge. Adam (after a night at the hospital because of Amber's accident) gets mad at Cory, and Cory later thinks Adam's not happy there, is hurt that Adam's not in agreement with him, and fires Adam. Gilliam T. Blount (Richard Dreyfuss) is a former Broadway producer who served in Vietnam, where Zeek saved his life. He helps Sarah with her play and produces it in season 2. Zoe DeHaven (Rosa Salazar) is the "coffee girl" who was carrying the baby that Julia and Joel planned to adopt. However, after the baby was born, she decided to keep him. Amy Ellis (Skyler Day) is Drew's girlfriend during parts of seasons 3 and 4, and stays at Drew's dorm room for several weeks when she does not want to return to Tufts in season 5. Dr. Joe Prestridge (D. B. Woodside), aka "Dr. Joe", is Jabbar's pediatrician who dates Jasmine in season 3. He asks her and Jabbar to move in with him, but she reconciles with and marries Crosby instead. Rachel (Alexandra Daddario) is Adam and Crosby's assistant at their recording studio, The Luncheonette during season 3.
== External links == Hepatocyte+growth+factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Hepatocyte growth factor on the Atlas of Genetics and Oncology UCSD Signaling Gateway Molecule Page on HGF Overview of all the structural information available in the PDB for UniProt: P14210 (Hepatocyte growth factor) at the PDBe-KB.
==== Luminal ions ==== In addition to NAADP gating the channel, there is evidence that the luminal pH also affects TPC channel activity, either TPC1 [1] or TPC2 [2][3]. However, a clear consensus on the effect of pH has not been reached with some suggesting that acidic pH favours TPC1 or TPC2 opening, whereas others report that a more alkaline pH favours TPC2 opening. Furthermore, luminal Ca2+ also promotes TPC1 and TPC2 opening (in the latter case, luminal Ca2+ also sensitizes TPCs to NAADP (analogous to luminal Ca2+ regulation of IP3Rs and RyRs), but this demands wider study across isoforms and species. This is one way by which cross-talk can occur between acidic Ca2+ stores and the ER i.e. Ca2+ release from the ER can 'prime' acidic Ca2+ stores and promote further NAADP-dependent Ca2+ responses [4].
Sources: en.wikipedia.org
The effect known as "the wedge" is the most widely known example of cold air damming. In this scenario, the more equatorward storm system will bring warmer air with it above the surface (at around 1,500 metres (4,900 ft)). This warmer air will ride over the cooler air at the surface, which is being held in place by the poleward high-pressure system. This temperature profile, known as a temperature inversion, will lead to the development of drizzle, rain, freezing rain, sleet, or snow. When it is above freezing at the surface, drizzle or rain could result. Sleet, or Ice pellets, form when a layer of above-freezing air exists with sub-freezing air both above and below it. This causes the partial or complete melting of any snowflakes falling through the warm layer. As they fall back into the sub-freezing layer closer to the surface, they re-freeze into ice pellets. However, if the sub-freezing layer beneath the warm layer is too small, the precipitation will not have time to re-freeze, and freezing rain will be the result at the surface. A thicker or stronger cold layer, where the warm layer aloft does not significantly warm above the melting point, will lead to snow.
== Professional career == Following her graduation in 1958, Susan Leeman was offered a one-year position as an instructor in the Physiology Department at Harvard Medical School. Realizing she was only a fill-in, the following year she took a job at Brandeis University where she stayed for the next 12 years. During this time she received a Career Development Award which helped her to balance her career and family life. Leeman's research while at Brandeis University mainly focused on the effect a corticotropin-releasing factor (CRF) had on the secretion of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland. During her effort to purify the CRF, she discovered a peptide that could stimulate the secretion of saliva. This caused her to switch the direction of the project entirely, as she decided to further investigate this peptide. Eventually Leeman and her lab realized she had unintentionally isolated substance P – a peptide originally discovered by Ulf von Euler in the 1930s, but had yet to be chemically defined. Leeman went on to discover the amino acid sequence of substance P and published her findings in the Journal of Biological Chemistry in 1970. During the purification process of substance P, Leeman and a graduate student of hers discovered a different peptide that was distributed throughout the central nervous system, gastrointestinal tract, and immune system, but had yet to be identified. They decided to name their discovery “neurotensin”.
== History == Arenobufagin is a component of a certain toad toxin which goes by the name of Chan’su. For centuries, this toxin has been used in Chinese traditional medicine in the treatment of liver cancer. Also, it is reported to have a stimulative effect upon the heart. It is derived from the dried skin secretions of certain toads. In a 2013 study, it was shown that arenobufagin inhibits the growth of certain liver tumor cells. In fact, this compound showed the most potent antitumor activity of fifteen bufadionolides isolated from Chan’su.
He added that "China's sovereignty, security, and development interests cannot be violated, and four red lines — the Taiwan question, democracy and human rights, development paths and systems, and development rights — cannot be challenged". Shortly after Xi arrived to the US on September 23, Treasury Secretary Bessent announced that the trade truce between the two countries, reached at the Busan Summit and was set to expire on November 10, would be extended until January 10, 2027. On September 24, Chinese defense ministry spokesperson Jiang Bin said that "it should be emphasized that the Taiwan question is the most important in China–US relations and maintaining peace and stability in the Taiwan Strait is the greatest common issue of the two countries and that "it is hoped that the US side will handle the Taiwan issue with extreme caution". Due to Trump's recent ban of several news outlets from the White House, most of Xi's state visit was not covered by the White House press pool. ABC World News Tonight placed the news of Xi's as the third item, with only photos and no video. CNN reported that the Chinese side had informally expressed its concerns to the United States that the boycott would affect the coverage of the visit. On September 24, the Trump administration returned the press credentials to the three media outlets, but still excluded CNN. The opening remarks of the summit meeting that day were not made public to the media as is customary, meaning the only publicly available video recording of the meeting was the segment broadcast by China Central Television.
GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS. GeneDx was founded in 2000 by Sherri Bale and John Compton, scientists from the National Institutes of Health (NIH), to provide diagnostic services for patients with rare and ultra-rare disorders. The company was acquired by BioReference Laboratories in 2006 and subsequently by Sema4 in 2022, after which it underwent a strategic transformation refocusing on whole exome and genome sequencing in pediatrics and changed its name to GeneDx. Since launching exome testing in 2011, the company has built GeneDx Infinity, a large and diverse rare disease dataset including more than one million clinically sequenced exomes and genomes, more than 2.5 million tests, and more than 8 million phenotypic datapoints. In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter. For full-year 2025, the company reported revenue of approximately $427 million.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.